Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 2

Safety and tolerability of antipsychotics: focus on amisulpride

Authors Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira

Published 1 October 2010 Volume 2010:2 Pages 205—211

DOI http://dx.doi.org/10.2147/DHPS.S6226

Review by Single-blind

Peer reviewer comments 3

Mario F Juruena1, Eduardo Pondé de Sena2, Irismar Reis de Oliveira3
1Stress and Affective Disorders Programme, Department of Neuroscience and Behaviour, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil; 2Department of Pharmacology, Institute of Health Sciences, Federal University of Bahia, Salvador; 3Department of Neurosciences and Mental Health, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil

Abstract: The introduction of the atypical antipsychotic drugs represents an important advance in the treatment of schizophrenia, because the therapeutic efficacy, tolerability, and safety profiles of these agents seem to be superior to that of the classical neuroleptics. As would be predicted from the pharmacologic profile of a pure D2/D3 receptor blocker, amisulpride is an atypical antipsychotic agent, effective for positive and negative symptoms, which can bring about additional improvement in the social functioning and quality of life of patients with schizophrenia. Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression scores. The major concern regarding the safety of the atypical antipsychotics is related to their propensity to induce weight gain and alter glucose and lipid metabolism. Amisulpride has one of the lowest potentials for weight gain of all the antipsychotic agents, and is associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. Amisulpride is well tolerated with regard to anxiety and insomnia, and not notably different from placebo. Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Hyperprolactinemia rapidly reverses following amisulpride discontinuation. Amisulpride benefits patients with negative symptoms, and is the only antipsychotic to demonstrate efficacy in patients with predominantly negative symptoms. Amisulpride maintains its efficacy when used for medium/long-term treatment, as demonstrated in studies of up to 12 months. In terms of relevance of the effects, superiority is observed for quality of life, social adaptation, and functioning, as measured by the Quality of Life and Functional Status Questionnaire scales. In conclusion, amisulpride is an antipsychotic agent with proven efficacy and good tolerability. Moreover, this drug can help people with schizophrenia to attain social reinsertion.
Keywords: amisulpride, antipsychotic agents, safety, adverse events, tolerability
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other article by this author:

Readers of this article also read:

Attrition of Canadian Internet pharmacy websites: what are the implications?

Veronin MA, Clancy KM

Drug, Healthcare and Patient Safety 2013, 5:171-179

Published Date: 15 August 2013

A case of congenital unilateral absence of the vas deferens

Mo B, Garla V, Wyner LM

International Medical Case Reports Journal 2013, 6:21-23

Published Date: 15 April 2013

Techniques for fabrication and construction of three-dimensional scaffolds for tissue engineering

Lu T, Li Y, Chen T

International Journal of Nanomedicine 2013, 8:337-350

Published Date: 18 January 2013

An update on the detection and treatment of Rickettsia felis

Hun L, Troyo A

Research and Reports in Tropical Medicine 2012, 3:47-55

Published Date: 22 June 2012

Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers

Elisabet Ekman, Staffan Hägg, Anders Sundström, et al

Drug, Healthcare and Patient Safety 2010, 2:21-25

Published Date: 29 March 2010

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Bryan A Faller, Barbara Burtness

Biologics: Targets and Therapy 2009, 3:419-428

Published Date: 14 September 2009

Effect of noninvasive mechanical ventilation in elderly patients with hypercapnic acute-on-chronic respiratory failure and a do-not-intubate order

Paolo Scarpazza, Cristoforo Incorvaia, Giuseppe di Franco, Stefania Raschi, Pierfranco Usai, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:797-801

Published Date: 5 December 2008

Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences

Carlos Zamarrón, Vanesa García Paz, Emilio Morete, Felix del Campo Matías

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:671-682

Published Date: 5 December 2008

Aripiprazole: the evidence of its therapeutic impact in schizophrenia

William Winlow, Louise Profit, Paul Chrisp

Core Evidence 2006, 1-Issues 3 & 4:0-0

Published Date: 30 June 2006